Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TXN10128 + paclitaxel
- Development stage
- Phase 1
- Lead developer
- Txinno Bioscience
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**TXN10128 + paclitaxel** is an investigational combination therapy being studied in adults with locally advanced or metastatic solid tumors that have relapsed or are refractory to standard treatment. TXN10128 is a small molecule inhibitor of ENPP1 (Ectonucleotide pyrophosphatase/phosphodiesterase family member 1), designed to disrupt ENPP1-mediated pathways involved in tumor progression. Paclitaxel is a well-established microtubule-stabilizing chemotherapeutic agent that inhibits cell division, approved for multiple cancer indications. The combination is delivered as oral TXN10128 and intravenous paclitaxel, with a Phase 1 clinical trial currently recruiting to evaluate safety, pharmacokinetics, pharmacodynamics, and antitumor activity in solid tumors, including specific arms for breast cancer patients[1][2].
- Other names
- TXN10128 + paclitaxel
02
Targets
ENPP1TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on TXN10128 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TXN10128 + paclitaxel.